These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 32036188)
21. Supply-Side Drug Policy in the Presence of Substitutes: Evidence from the Introduction of Abuse-Deterrent Opioids. Alpert A; Powell D; Pacula RL Am Econ J Econ Policy; 2018 Nov; 10(4):1-35. PubMed ID: 34326924 [TBL] [Abstract][Full Text] [Related]
23. Monitoring of internet forums to evaluate reactions to the introduction of reformulated OxyContin to deter abuse. McNaughton EC; Coplan PM; Black RA; Weber SE; Chilcoat HD; Butler SF J Med Internet Res; 2014 May; 16(5):e119. PubMed ID: 24800858 [TBL] [Abstract][Full Text] [Related]
24. Reformulation of oxycodone 80 mg to prevent misuse: A cohort study assessing the impact of a supply-side intervention. Nolan ML; Harocopos A; Allen B; Paone D Int J Drug Policy; 2020 Sep; 83():102848. PubMed ID: 32645583 [TBL] [Abstract][Full Text] [Related]
25. Recent trends in heroin and pharmaceutical opioid-related harms in Victoria, Australia up to 2018. Lam T; Kuhn L; Hayman J; Middleton M; Wilson J; Scott D; Lubman DI; Smith K; Nielsen S Addiction; 2020 Feb; 115(2):261-269. PubMed ID: 31465131 [TBL] [Abstract][Full Text] [Related]
26. Use of prescription opioids with abuse-deterrent technology to address opioid abuse. Michna E; Kirson NY; Shei A; Birnbaum HG; Ben-Joseph R Curr Med Res Opin; 2014 Aug; 30(8):1589-98. PubMed ID: 24738694 [TBL] [Abstract][Full Text] [Related]
27. Heterogeneity in Prescription Opioid Pain Reliever Misuse Across Age Groups: 2015-2017 National Survey on Drug Use and Health. Schuler MS; Dick AW; Stein BD J Gen Intern Med; 2020 Mar; 35(3):792-799. PubMed ID: 31792871 [TBL] [Abstract][Full Text] [Related]
28. Adults who misuse opioids: Substance abuse treatment use and perceived treatment need. Choi NG; DiNitto DM; Marti CN; Choi BY Subst Abus; 2019; 40(2):247-255. PubMed ID: 30810503 [No Abstract] [Full Text] [Related]
29. A tale of 2 ADFs: differences in the effectiveness of abuse-deterrent formulations of oxymorphone and oxycodone extended-release drugs. Cicero TJ; Ellis MS; Kasper ZA Pain; 2016 Jun; 157(6):1232-1238. PubMed ID: 27186712 [TBL] [Abstract][Full Text] [Related]
30. Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties. Gudin J; Levy-Cooperman N; Kopecky EA; Fleming AB Pain Med; 2015 Nov; 16(11):2142-51. PubMed ID: 26108255 [TBL] [Abstract][Full Text] [Related]
31. Discrepancies in prevalence estimates in two national surveys for nonmedical use of a specific opioid product versus any prescription pain reliever. Biondo G; Chilcoat HD Drug Alcohol Depend; 2014 Jan; 134():396-400. PubMed ID: 24210422 [TBL] [Abstract][Full Text] [Related]
32. The epidemiology of prescription fentanyl misuse in the United States. Schepis TS; McCabe VV; Boyd CJ; McCabe SE Addict Behav; 2019 Sep; 96():89-93. PubMed ID: 31063940 [TBL] [Abstract][Full Text] [Related]
33. The impact of OxyContin reformulation at the Sydney Medically Supervised Injecting Centre: Pros and cons. Jauncey M; Livingston M; Salmon AM; Dietze P Int J Drug Policy; 2018 Mar; 53():17-22. PubMed ID: 29268238 [No Abstract] [Full Text] [Related]
34. Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS) System Web Monitoring Program. Vosburg SK; Haynes C; Besharat A; Green JL Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1044-1052. PubMed ID: 28653782 [TBL] [Abstract][Full Text] [Related]
35. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010. Severtson SG; Bartelson BB; Davis JM; Muñoz A; Schneider MF; Chilcoat H; Coplan PM; Surratt H; Dart RC J Pain; 2013 Oct; 14(10):1122-30. PubMed ID: 23816949 [TBL] [Abstract][Full Text] [Related]
36. Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users. Harris SC; Perrino PJ; Smith I; Shram MJ; Colucci SV; Bartlett C; Sellers EM J Clin Pharmacol; 2014 Apr; 54(4):468-77. PubMed ID: 24243216 [TBL] [Abstract][Full Text] [Related]
37. Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers - United States, 2002-2004 and 2008-2010. Jones CM Drug Alcohol Depend; 2013 Sep; 132(1-2):95-100. PubMed ID: 23410617 [TBL] [Abstract][Full Text] [Related]
38. Understanding the rise in overdose deaths involving opioids and non-opioid prescription drugs in the United States. Powell D; Peet ED; Pacula RL Int J Drug Policy; 2023 Jul; ():104104. PubMed ID: 37422359 [TBL] [Abstract][Full Text] [Related]